International Journal of Obesity, 2025
What Both Medications Do Inside the Body Although the delivery systems differ, both medications activate the GLP-1 receptor and trigger similar downstream effects: Increased insulin release in response to elevated blood sugar Reduced glucagon secretion Slower gastric emptying Reduced appetite signaling Increased satiety after meals According to the National Institute of Diabetes and Digestive and Kidney Diseases, these mechanisms can support improved blood sugar regulation and meaningful weight reduction when combined with lifestyle interventions
Additionally, a systematic review found that patients on orforglipron had significantly better weight loss outcomes, achieving reductions of 5%, 10%, and 15%
The STEP 1 trial showed that 86.4 percent of participants achieved at least 5 percent weight loss, 69.1 percent reached 10 percent, 50.5 percent hit 15 percent, and 32 percent achieved 20 percent or greater weight loss
Delays gastric transit to slow glucose absorption and extend satiety signals